Generic Name and Formulations:
Netarsudil 0.02%; oph soln; contains benzalkonium chloride.
Aerie Pharmaceuticals, Inc.
RECENT UPDATESMonograph added.
Indications for RHOPRESSA:
Open-angle glaucoma. Ocular hypertension.
≥18yrs: Instill 1 drop into the affected eye(s) once daily in the PM.
<18yrs: not established.
Concurrent corneal disease or disruption of the ocular epithelial surface. Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Allow at least 5mins between application of other topical oph agents.
Rho kinase inhibitor.
Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage; bacterial keratitis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Hospitalization Rates in Schizophrenia—Lurasidone vs Quetiapine
- Psychopathology of Adults Affected by Pre- and Perinatal Factors, Family Functioning
- Anxiety: Feature of Late-Onset Dementia or Modifiable Risk Factor?
- Family History of Psychiatric Disorders an Important Predictor of Postpartum Psychiatric Illness
- New APA President Takes Office as the First African-American to Lead the Organization
- Video Games and Exercise as Alternative Therapies for ADHD
- How Parents Can Enhance Autism Treatment: Use of Intervention Strategies at Home
- Electroconvulsive Therapy Effective in Children With Autism
- The Cutting Edge of Schizophrenia Research: VR as Treatment for Psychosis
- Comorbid Autism Spectrum Disorder and OCD: Challenges in Diagnosis and Treatment
- Addressing Psychiatric Comorbidities in Inflammatory Rheumatic Diseases
- Exploring the Link Between Persistent Infection, Inflammation, and Mood Disorders
- CDC: No Change in Level of Uninsured in US in 2017
- Benefit of Behavioral Activation During TMS for Major Depressive Disorder
- Global Prevalence of Alcohol, Tobacco, and Illicit Drug Use: A 2017 Status Report